Company intelligence / Profile preview

Actxa

Singapore, Singaporeactxa.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

Actxa has developed and commercialized BGEM—the world’s first non-invasive AI-powered blood glucose monitoring solution—enabling early detection of prediabetes and Type 2 diabetes risk. The company’s digital health platforms are used in large-scale preventive health programs such as Singapore’s National Steps Challenge™. Clinical validation details are not specified but the technology has been adopted for population-level use.

Therapeutic areas: OtherEndocrinology
Modalities: Device (wearable)Digital health platformArtificial intelligence-based solution
Industry: Physiological Monitoring

Partnerships

Instytut Medycyny Innowacyjnej sp.z o.o. (“IMI”), Poland – distribution/licensing partnership for BGEM and other technologies in Europe.

Beyond the preview

Go deeper on Actxa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actxa.

Explore the full profile